Traders should monitor enrollment progress and upcoming clinical milestones in the Phase 3 program, as the next major catalyst will be topline data in late 2027. The safety profile supports further development but does not de-risk late-stage trial outcomes.
Price Chart
Executive Summary
Minerva Neurosciences announced positive safety data from an open-label trial showing no clinically significant adverse effects or drug interactions when roluperidone is co-administered with olanzapine, a commonly used antipsychotic. The company is advancing its Phase 3 confirmatory trial for roluperidone in schizophrenia's negative symptoms, with topline data expected in the second half of 2027.
Key Facts
- No safety concerns or clinically significant pharmacokinetic/pharmacodynamic changes observed when roluperidone is combined with olanzapine.
- Data presented at the 2026 Schizophrenia International Research Society (SIRS) Congress.
- Phase 3 confirmatory trial for roluperidone is currently enrolling; topline results expected in second half of 2027.
- Roluperidone is being developed for the treatment of negative symptoms of schizophrenia.
Financial Impact
No immediate financial impact; long-term commercial potential remains contingent on Phase 3 success.
Risk Factors
- Phase 3 trial may fail to meet efficacy endpoints despite favorable safety data.
- Roluperidone faces competitive and regulatory uncertainty in the schizophrenia treatment landscape.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262573 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 8-K | $3.92 | awaiting T+60 | — | $2.20 (−43.88%) |
Aug 7, 2026 11w ago | 8-K | $4.27 | awaiting T+60 | — | $2.20 (−48.48%) |
May 27, 2026 21w ago | 8-K | $5.00 $4.84 | ▲ +3.20% | ▲ +4.93% | $2.20 (+56.00%) |
May 5, 2026 24w ago | 8-K | $6.25 $4.02 | ▼ −35.68% | ▼ −38.42% | $2.20 (−64.80%) |
Apr 23, 2026 26w ago | DEFA14A | $6.83 $4.37 | ▼ −36.02% | ▼ −41.04% | $2.20 (−67.79%) |
Mar 25, 2026 30w ago | Press Release | $6.14 $4.66 | ▼ −24.10% | ▼ −38.05% | $2.20 (−64.17%) |
Mar 20, 2026 31w ago | EFFECT | $7.54 $4.39 | ▼ −41.78% | ▼ −56.20% | $2.20 (−70.82%) |
Mar 11, 2026 32w ago | S-3 | $7.30 $4.68 | ▲ +35.89% | ▲ +47.41% | $2.20 (+69.86%) |
Mar 11, 2026 32w ago | Press Release | $7.30 $4.68 | ▼ −35.89% | ▼ −47.41% | $2.20 (−69.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers